YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
When biopharmaceutical companies advance platform technologies targeting complex immunological pathways, market participants must weigh clinical efficacy against the heavy capital requirements of drug development. Celldex Therapeutics (NAS…
For Immediate Release Chicago, IL – September 23, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financia…
Clinical readouts are among the most important catalysts for biotechnology stocks, as study results can materially shift investor expectations about a drug candidate's efficacy, safety, regulatory prospects and commercial potential. Positi…
Celldex Therapeutics' (CLDX) two Phase 3 trials of barzolvolimab in patients with chronic spontaneou PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Celldex Therapeutics, Inc. Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab's potential to be a transformational therapy in CSU EMBARQ-CSU1 and -CSU2 met primary and all key secondary endpoints a…
Celldex Therapeutics, Inc. HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 202…
(RTTNews) - The following biotech stocks reached a 52-week high on August 10, 2026, driven by key catalysts such as positive quarterly reports or the release of promising results from clinical trials. Silence Therapeutics plc (SLN) Silence…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Celldex Therapeutics (CLDX) released its second quarter 2026 results on 6 August, reporting very limited revenue and a wider…
Celldex Therapeutics, Inc. recently reported second-quarter 2026 results, with revenue falling to US$0.022 million and net loss widening to US$73.5 million, while loss per share from continuing operations increased to US$0.94. Over the fir…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Celldex Therapeutics stock has more than doubled over the past year, yet its broader valuation ch…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Celldex Therapeutics (NasdaqCM:CLDX) reported updated clinical pipeline data, including positive Phase 1 results for bispeci…
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $0.85 per share a year ago. These figures are adjusted for non-recurring items…
Celldex Therapeutics, Inc. Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027 Phase 3 barzolvolimab cold urticaria and symptomat…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Celldex Therapeutics (CLDX) is a stock that can certainly grab the attention of many investors, but do…
(RTTNews) - Celldex (CLDX) reported topline results from the Phase 2 study of Barzolvolimab in Prurigo Nodularis or PN, indicating that the study did not meet the primary endpoint and key secondary endpoints. Following the results, Celldex…
Celldex Therapeutics, Inc. Study did not meet key efficacy objectives Favorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimen Profound systemic mast cell depletion, as eviden…
(RTTNews) - Celldex (CLDX), an immunology company, announced that Sam Martin, the company's Senior Vice President and Chief Financial Officer (CFO), has informed the company of his plans to retire in 2027. Following that, Celldex has initi…
Celldex Therapeutics, Inc. HAMPTON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Officer, has informed the Company of his plans to retire in 2027.…
We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the best biotech stocks on this list. TheFly reported on June 10 that UBS increased its price target…
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is one of the best low-priced pharma stocks on this list. TheFly reported on June 11 that XERS announced tha…
The chronic spontaneous urticaria market is witnessing significant growth, driven by increasing disease awareness, improved diagnosis rates, and the rising prevalence of treatment-refractory patients. The introduction of emerging therapies…
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s. Previous close: $26.99. An 81% gain, ov…
(RTTNews) - This week, the biotech sector saw FDA approvals, alongside study halts, layoffs, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical readouts spanning therapeutic areas includ…
(RTTNews) - Celldex (CLDX), a biopharmaceutical company, on Sunday reported positive data from the Phase 2b trial showing sustained effects of Barzolvolimab in treating Angioedema in patients with chronic spontaneous urticaria. Results wer…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Celldex Therapeutics (CLDX) has attracted fresh attention after a recent move in its share price, with the stock closing at US$31.2…
Celldex Therapeutics, Inc. Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU Seven months after the completion of dosing (Week 76), up to 64% of pati…
Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSUSeven months after the completion of dosing (Week 76), up to 64% of patients treated with barzolvoli…
Celldex Therapeutics, Inc. CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseases CDX-622 targets the soluble form of stem cell factor (SCF)…
CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseasesCDX-622 targets the soluble form of stem cell factor (SCF), depleting mast cells witho…
Celldex Therapeutics, Inc. -- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria -- -- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced to…
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Cholera Vaccine Market size & share revenue was valued at approximately USD 312 Millio…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Celldex Therapeutics stock overview Celldex Therapeutics (CLDX) has been drawing investor attention after recent tradin…
Celldex Therapeutics (CLDX) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $0.81 per share a year ago. These figures are adjusted for non-recurring items.…
Celldex Therapeutics, Inc. Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for 2027 Phase 3…
Shares of Celldex Therapeutics (CLDX) have gained 4% over the past four weeks to close the last trading session at $32.31, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are an…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. If you are wondering whether Celldex Therapeutics at around US$33.2…